Biogen on Wednesday reported first-quarter earnings that beat Wall Street expectations largely on reduced expenses. Total revenue was slightly weak overall, but sales were stronger for two newly launched medicines — Leqembi and Skyclarys — that matter most to the biotech’s turnaround effort.
Shares rose 5% to $202 in early trading.
Here’s what you need to know from Biogen’s earnings and conference call:
The suspected shooter in an hours-long standoff in Atlanta on Tuesday afternoon has been identified as retired ophthalmologist Jay Berger, MD. The 70-year-old was taken
Researchers from the University of Oslo have developed an innovative tool that promises to improve our understanding of heritable human traits and diseases.
Researchers presented a scalable lipid nanoparticle production (SCALAR) platform to develop SARS-CoV-2 mRNA lipid nanoparticle vaccines.